-
Good News from Aerie Pharma; Aratana Therapeutics Should Cheer Investors
Thursday, February 18, 2016 - 11:08am | 496Read More...Aerie Pharmaceuticals Inc (NASDAQ: AERI) and Aratana Therapeutics Inc (NASDAQ: PETX) have come out with positive announcements that should cheer investors on Thursday. Aerie Pharma reported the successful 12-month interim safety results of Rocket 2, Aerie's second Phase 3 registration trial for...
-
Watch Out Below: 'Sluggish' MannKind Double-Downgraded By RBC Analyst
Wednesday, November 4, 2015 - 10:26am | 317Read More...MannKind Corporation (NASDAQ: MNKD) shares are down 2 percent since October 5, after volatility through the month. RBC Capital Markets’ Adnan Butt downgraded the rating on the company from Outperform to Underperform, while reducing the price target from $9 to $1. Physician survey...
-
UPDATE: RBC Capital Markets Upgrades AVEO Pharmaceuticals On Progress In Multiple Areas
Monday, March 9, 2015 - 8:38am | 112Read More...In a report published Monday, RBC Capital Markets analyst Adnan Butt upgraded the rating on AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from Underperform to Sector Perform, and raised the price target from $2.00 to $3.00. In the report, RBC Capital Markets noted, "Since the setback with tivozanib in...
-
RBC Optimistic on Regeneron Following Lower Sales by Novartis' Lucentis
Thursday, April 24, 2014 - 4:31pm | 216Read More...RBC Capital Markets analyst Adnan Butt is optimistic on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) following lower sales outside the US by competing Novartis AG (NYSE: NVS) drug Lucentis. Lucentis, is a ranibizumab injection for the treatment of wet age-related macular degeneration...
